Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

BACKGROUND: Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). METHODS: This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. RESULTS: Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. CONCLUSIONS: In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-16
DOI
https://doi.org/10.1371/journal.pone.0355518
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

Thang Viet Luong, Hung Minh Nguyen, Phuc Thien Tran, Binh Anh Ho et al.
PLoS ONE
Antiplatelet Therapy and Cardiovascular Diseases
article

Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

Thang Viet Luong, Hung Minh Nguyen, Phuc Thien Tran, Binh Anh Ho, Hai Nguyen Ngoc Dang, Tan Van Nguyen
article en

Abstract

BACKGROUND: Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). METHODS: This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. RESULTS: Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40-1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93-2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79-1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15-0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07-3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05-4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. CONCLUSIONS: In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.

PLoS ONEVol. 21(11)
University of Tasmania (AU), Duy Tan University (VN), University of Medicine and Pharmacy at Ho Chi Minh City (VN), Hue Central Hospital (VN), Bạch Mai Hospital (VN), Thong Nhat Hospital (VN)
Good health and well-being
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon